Cardiac Failure Review最新文献_第6页

Isolated Left Ventricular Apical Hypoplasia. 孤立性左心室顶端发育不全。

Cardiac Failure Review Pub Date : 2021-12-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.24

Abhishek Dattani, Rachana Prasad

引用次数: 2

The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. 空白填补:快速启动和最佳滴定综合疾病改善药物治疗心力衰竭与降低射血分数的基本原理。

Cardiac Failure Review Pub Date : 2021-11-26 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.18

Nicholas K Brownell, Boback Ziaeian, Gregg C Fonarow

引用次数: 19

Cardiac Sarcoidosis: When and How to Treat Inflammation. 心脏结节病:何时及如何治疗炎症。

Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.16

Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala

{"title":"Cardiac Sarcoidosis: When and How to Treat Inflammation.","authors":"Gerard T Giblin, Laura Murphy, Garrick C Stewart, Akshay S Desai, Marcelo F Di Carli, Ron Blankstein, Michael M Givertz, Usha B Tedrow, William H Sauer, Gary M Hunninghake, Paul F Dellaripa, Sanjay Divakaran, Neal K Lakdawala","doi":"10.15420/cfr.2021.16","DOIUrl":"https://doi.org/10.15420/cfr.2021.16","url":null,"abstract":"Sarcoidosis is a complex, multisystem inflammatory disease with a heterogeneous clinical spectrum. Approximately 25% of patients with systemic sarcoidosis will have cardiac involvement that portends a poorer outcome. The diagnosis, particularly of isolated cardiac sarcoidosis, can be challenging. A paucity of randomised data exist on who, when and how to treat myocardial inflammation in cardiac sarcoidosis. Despite this, corticosteroids continue to be the mainstay of therapy for the inflammatory phase, with an evolving role for steroid-sparing and biological agents. This review explores the immunopathogenesis of inflammation in sarcoidosis, current evidence-based treatment indications and commonly used immunosuppression agents. It explores a multidisciplinary treatment and monitoring approach to myocardial inflammation and outlines current gaps in our understanding of this condition, emerging research and future directions in this field.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e17"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ba/e7/cfr-07-e17.PMC8674699.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 17

Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors. 心房颤动引起的左心室收缩功能障碍:临床和超声心动图预测因素。

Cardiac Failure Review Pub Date : 2021-11-22 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.17

Erez Marcusohn, Ofer Kobo, Maria Postnikov, Danny Epstein, Yoram Agmon, Lior Gepstein, Yaron Hellman, Robert Zukermann

{"title":"Left Ventricular Systolic Dysfunction Due to Atrial Fibrillation: Clinical and Echocardiographic Predictors.","authors":"Erez Marcusohn, Ofer Kobo, Maria Postnikov, Danny Epstein, Yoram Agmon, Lior Gepstein, Yaron Hellman, Robert Zukermann","doi":"10.15420/cfr.2021.17","DOIUrl":"https://doi.org/10.15420/cfr.2021.17","url":null,"abstract":"Background: Diagnosis of AF-induced cardiomyopathy can be challenging and relies on ruling out other causes of cardiomyopathy and, after restoration of sinus rhythm, recovery of left ventricular (LV) function. The aim of this study was to identify clinical and echocardiographic predictors for developing cardiomyopathy with systolic dysfunction in patients with atrial tachyarrhythmia. Methods: This retrospective study was conducted in a large tertiary care centre and compared patients who experienced deterioration of LV ejection fraction (EF) during paroxysmal AF, demonstrated by precardioversion transoesophageal echocardiography with patients with preserved LV function during AF. All patients had documented preserved LVEF at baseline (EF >50%) while in sinus rhythm. Results: Of 482 patients included in the final analysis, 80 (17%) had reduced and 402 (83%) had preserved LV function during the precardioversion transoesophageal echocardiography. Patients with reduced LVEF were more likely to be men and to have a more rapid ventricular response during AF or atrial flutter (AFL). A history of prosthetic valves was also identified as a risk factor for reduced LVEF. Patients with reduced LVEF also had higher incidence of tricuspid regurgitation and right ventricular dysfunction. Conclusion: In 'real-world' experience, male patients with rapid ventricular response during paroxysmal AF or AFL are more prone to LVEF reduction. Patients with prosthetic valves are also at risk for LVEF reduction during AF/AFL. Finally, tricuspid regurgitation and right ventricular dysfunction may indicate relatively long-standing AF with an associated reduction in LVEF.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e16"},"PeriodicalIF":0.0,"publicationDate":"2021-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/3a/cfr-07-e16.PMC8674700.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy. 他汀类药物强度对同种异体心脏移植血管病变进展的影响。

Cardiac Failure Review Pub Date : 2021-11-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.07

Tracey M Ellimuttil, Kimberly Harrison, Allman T Rollins, Irene D Feurer, Scott A Rega, Jennifer Gray, Jonathan N Menachem

{"title":"Effect of Statin Intensity on the Progression of Cardiac Allograft Vasculopathy.","authors":"Tracey M Ellimuttil, Kimberly Harrison, Allman T Rollins, Irene D Feurer, Scott A Rega, Jennifer Gray, Jonathan N Menachem","doi":"10.15420/cfr.2021.07","DOIUrl":"https://doi.org/10.15420/cfr.2021.07","url":null,"abstract":"Background: In the non-transplant population, hyperlipidaemia has shifted from targeting LDL goals to statin intensity-based treatment. It is unknown whether this strategy is also beneficial in cardiac transplantation. Methods: This single-centre retrospective study evaluated the effect of statin use and intensity on time to cardiac allograft vasculopathy (CAV) after cardiac transplantation. Kaplan-Meier and Cox proportional hazards regression survival methods were used to assess the association of statin intensity and median post-transplant LDL on CAV-free survival. Results: The study involved 143 adults (71% men, average follow-up of 25 ± 14 months) who underwent transplant between 2013 and 2017. Mean CAV-free survival was 47.5 months (95% CI [43.1-51.8]), with 29 patients having CAV grade 1 or greater. Median LDL was not associated with time to CAV (p=0.790). CAV-free survival did not differ between intensity groups (p=0.435). Conclusion: Given the non-statistically significant difference in time to CAV with higher intensity statins, the data suggest that advancing moderate- or high-intensity statin after cardiac transplantation may not provide additional long-term clinical benefit. Trial registration: Not applicable.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e15"},"PeriodicalIF":0.0,"publicationDate":"2021-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/e6/cfr-07-e15.PMC8609416.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39636569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to Implant His Bundle and Left Bundle Pacing Leads: Tips and Pearls. 如何植入他的束和左束起搏导线:提示和珍珠。

Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.04

Shunmuga Sundaram Ponnusamy, Pugazhendhi Vijayaraman

引用次数: 17

Unknown Risks of Transplantation in Adults with Congenital Heart Disease. 成人先天性心脏病移植的未知风险。

Cardiac Failure Review Pub Date : 2021-08-06 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.09

Aniket S Rali, Angela Weingarten, Emily Sandhaus, Richa Gupta, Allman Rollins, David Bichell, Nhue Do, D Marshall Brinkley, Kelly H Schlendorf, Daniel Freno, Keki Balsara, Jonathan N Menachem

引用次数: 1

Evaluation and Management of Heart Block After Transcatheter Aortic Valve Replacement. 经导管主动脉瓣置换术后心脏传导阻滞的评价与处理。

Cardiac Failure Review Pub Date : 2021-07-27 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.05

Anthony J Mazzella, Sameer Arora, Michael J Hendrickson, Mason Sanders, John P Vavalle, Anil K Gehi

{"title":"Evaluation and Management of Heart Block After Transcatheter Aortic Valve Replacement.","authors":"Anthony J Mazzella, Sameer Arora, Michael J Hendrickson, Mason Sanders, John P Vavalle, Anil K Gehi","doi":"10.15420/cfr.2021.05","DOIUrl":"https://doi.org/10.15420/cfr.2021.05","url":null,"abstract":"Transcatheter aortic valve replacement (TAVR) has developed substantially since its inception. Improvements in valve design, valve deployment technologies, preprocedural imaging and increased operator experience have led to a gradual decline in length of hospitalisation after TAVR. Despite these advances, the need for permanent pacemaker implantation for post-TAVR high-degree atrioventricular block (HAVB) has persisted and has well-established risk factors which can be used to identify patients who are at high risk and advise them accordingly. While most HAVB occurs within 48 hours of the procedure, there is a growing number of patients developing HAVB after initial hospitalisation for TAVR due to the trend for early discharge from hospital. Several observation and management strategies have been proposed. This article reviews major known risk factors for HAVB after TAVR, discusses trends in the timing of HAVB after TAVR and reviews some management strategies for observing transient HAVB after TAVR.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e12"},"PeriodicalIF":0.0,"publicationDate":"2021-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ca/19/cfr-07-e12.PMC8353545.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39306121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure. 碳水化合物抗原125:心衰中充血和炎症十字路口的生物标志物。

Cardiac Failure Review Pub Date : 2021-06-12 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2021.22

Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Duska Glavas, Tina Saric, Bjørnar Marcelius, Domenico D'Amario, Josip A Borovac

{"title":"Carbohydrate Antigen 125: A Biomarker at the Crossroads of Congestion and Inflammation in Heart Failure.","authors":"Marko Kumric, Tina Ticinovic Kurir, Josko Bozic, Duska Glavas, Tina Saric, Bjørnar Marcelius, Domenico D'Amario, Josip A Borovac","doi":"10.15420/cfr.2021.22","DOIUrl":"https://doi.org/10.15420/cfr.2021.22","url":null,"abstract":"Because heart failure (HF) is more lethal than some of the common malignancies in the general population, such as prostate cancer in men and breast cancer in women, there is a need for a cost-effective prognostic biomarker in HF beyond natriuretic peptides, especially concerning congestion, the most common reason for the hospitalisation of patients with worsening of HF. Furthermore, despite diuretics being the mainstay of treatment for volume overload in HF patients, no randomised trials have shown the mortality benefits of diuretics in HF patients, and appropriate diuretic titration strategies in this population are unclear. Recently, carbohydrate antigen (CA) 125, a well-established marker of ovarian cancer, emerged as both a prognostic indicator and a guide in tailoring decongestion therapy for patients with HF. Hence, in this review the authors present the molecular background regarding the role of CA125 in HF and address valuable clinical aspects regarding the relationship of CA125 with both prognosis and therapeutic management in HF.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e19"},"PeriodicalIF":0.0,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d2/b9/cfr-07-e19.PMC8674624.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

The Future of Telemedicine in the Management of Heart Failure Patients. 远程医疗在心力衰竭患者管理中的未来。

IF 4.2

Cardiac Failure Review Pub Date : 2021-05-28 eCollection Date: 2021-03-01 DOI: 10.15420/cfr.2020.32

José Silva-Cardoso, José Ramón González Juanatey, Josep Comin-Colet, José Maria Sousa, Ana Cavalheiro, Emília Moreira

{"title":"The Future of Telemedicine in the Management of Heart Failure Patients.","authors":"José Silva-Cardoso, José Ramón González Juanatey, Josep Comin-Colet, José Maria Sousa, Ana Cavalheiro, Emília Moreira","doi":"10.15420/cfr.2020.32","DOIUrl":"10.15420/cfr.2020.32","url":null,"abstract":"Telemedicine (TM) is potentially a way of escalating heart failure (HF) multidisciplinary integrated care. Despite the initial efforts to implement TM in HF management, we are still at an early stage of its implementation. The coronavirus disease 2019 pandemic led to an increased utilisation of TM. This tendency will probably remain after the resolution of this threat. Face-to-face medical interventions are gradually transitioning to the virtual setting by using TM. TM can improve healthcare accessibility and overcome geographic inequalities. It promotes healthcare system efficiency gains, and improves patient self-management and empowerment. In cooperation with human intervention, artificial intelligence can enhance TM by helping to deal with the complexities of multicomorbidity management in HF, and will play a relevant role towards a personalised HF patient approach. Artificial intelligence-powered/telemedical/heart team/multidisciplinary integrated care may be the next step of HF management. In this review, the authors analyse TM trends in the management of HF patients and foresee its future challenges within the scope of HF multidisciplinary integrated care.","PeriodicalId":33741,"journal":{"name":"Cardiac Failure Review","volume":"7 ","pages":"e11"},"PeriodicalIF":4.2,"publicationDate":"2021-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/de/34/cfr-07-e11.PMC8201465.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39244542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0